Lisa Crowe

Lisa Crowe

Auto-generated profile, based on publicly available information

Lisa Crowe

Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2022 in Obesity Reviews
Verified
Journal Article
Open access
NHNicola Heslehurst
Nicola Heslehurst
LNLem Ngongalah
Lem Ngongalah
TBTheophile Bigirumurame
Theophile Bigirumurame
GNGiang Thu Nguyen
Giang Thu Nguyen
AOAdefisayo Odeniyi
Adefisayo Odeniyi
LHLouise Hayes
Louise Hayes
Summary: Maternal obesity increases pregnancy‐related risks. Women with a body mass index (BMI) ≥ 30 kg/m2 are considered to be at risk and should receive additional care, although approximately half will have uncomplicated pregnancies. This systematic review aimed to identify early pregnancy measures of adiposity associated with adverse maternal health outcomes. Searches included six databases, reference lists, citations, and contacting authors. Screening and quality assessment were carried out by two authors independently. Random effects meta‐analysis and narrative synthesis were conducted. Seventy studies were included with a pooled sample of 89,588 women. Meta‐analysis showed significantly increased odds of gestational diabetes mellitus (GDM) with higher waist circumference (WC) categories (1.40, 95% confidence interval [CI] 1.04, 1.88) and per unit increase in WC (1.31, 95% CI 1.03, 1.67). Women with GDM had higher WC than controls (mean difference [MD] 6.18 cm, 95% CI 3.92, 8.44). WC was significantly associated with hypertensive disorders, delivery‐related outcomes, metabolic syndrome, and composite pregnancy outcomes. Waist to hip ratio was significantly associated with GDM, hypertensive disorders, and delivery‐related outcomes. Fat mass, neck circumference, skinfolds, and visceral fat were significantly associated with adverse outcomes, although limited data were available. Our findings identify the need to explore how useful adiposity measures are at predicting risk in pregnancy, compared with BMI, to direct care to women with the greatest need.

1 September 2018 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
LCLisa Crowe
Lisa Crowe
RGRuth H. Graham
Ruth H. Graham
SRStephen C. Robson
Stephen C. Robson
JRJudith Rankin
Judith Rankin

8 July 2022 in Obesity Reviews
Verified
Journal Article
Open access
GNGiang Thu Nguyen
Giang Thu Nguyen
LHLouise Hayes
Louise Hayes
LNLem Ngongalah
Lem Ngongalah
TBTheophile Bigirumurame
Theophile Bigirumurame
LGLaura Gaudet
Laura Gaudet
NHNicola Heslehurst
Nicola Heslehurst
Summary: Maternal obesity increases risks of adverse fetal and infant outcomes. Guidelines use body mass index to diagnose maternal obesity. Evidence suggests body fat distribution might better predict individual risk, but there is a lack of robust evidence during pregnancy. We explored associations between maternal adiposity and infant health. Searches included six databases, references, citations, and contacting authors. Screening and quality assessment were carried out by two authors independently. Random effects meta‐analysis and narrative synthesis were conducted. We included 34 studies (n = 40,143 pregnancies). Meta‐analysis showed a significant association between maternal fat‐free mass and birthweight (average effect [AE] 18.07 g, 95%CI 12.75, 23.38) but not fat mass (AE 8.76 g, 95%CI −4.84, 22.36). Women with macrosomic infants had higher waist circumference than controls (mean difference 4.93 cm, 95% confidence interval [CI] 1.05, 8.82). There was no significant association between subcutaneous fat and large for gestational age (odds ratio 1.06 95% CI 0.91, 1.25). Waist‐to‐hip ratio, neck circumference, skinfolds, and visceral fat were significantly associated with several infant outcomes including small for gestational age, preterm delivery, neonatal morbidity, and mortality, although meta‐analysis was not possible for these variables. Our findings suggest that some measures of maternal adiposity may be useful for risk prediction of infant outcomes. Individual participant data meta‐analysis could overcome some limitations in our ability to pool published data.

1 March 2018 in BMJ Open
Verified
Journal Article
Open access
PDF file
LCLisa Crowe
Lisa Crowe
RGRuth H Graham
Ruth H Graham
SRStephen C Robson
Stephen C Robson
JRJudith Rankin
Judith Rankin
Objective This study aims to explore the perspectives of professionals around the issue of termination of pregnancy for non-lethal fetal anomaly (TOPFA). Methods Semi-structured interviews were undertaken with medical professionals (14 consultants in fetal medicine, obstetrics, neonatology and paediatrics) and social care professionals (nine individuals with roles supporting people living with impairment) from the Northeast of England. Analysis adopted an inductive thematic approach facilitated by NVivo. Results The overarching theme to emerge from the interview data was of professionals, medical and social care, wanting to present an acceptable self-image of their views on TOPFA. Professionals’ values on ‘fixing’, pain and ‘normality’ influenced what aspects of moral acceptability they gave priority to in terms of their standpoint and, in turn, their conceptualisations of acceptable TOPFA. Thus, if a termination could be defended morally, including negotiation of several key issues (including ‘fixing’, perceptions of pain and normality), then participants conceptualised TOPFA as an acceptable pregnancy outcome. Conclusion Despite different professional experiences, these professional groups were able to negotiate their way through difficult terrain to conceptualise TOPFA as a morally acceptable principle. While professionals have different moral thresholds, no one argued for a restriction of the current legislation. The data suggest that social care professionals also look at the wider social context of a person with an impairment when discussing their views regarding TOPFA. Medical professionals focus more on the individual impairment when discussing their views on TOPFA.

16 December 2019 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
LCLisa Crowe
Lisa Crowe
ESEmma Simpson
Emma Simpson
ZRZdenka Reinhardt
Zdenka Reinhardt
JRJudith Rankin
Judith Rankin

4 May 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
LCLisa Crowe
Lisa Crowe
MBMorven Brown
Morven Brown
ABAndy Bojke
Andy Bojke
RBRona Bojke
Rona Bojke
AGAlastair Greystoke
Alastair Greystoke
LSLinda Sharp
Linda Sharp
Introduction Biological and precision therapies are increasingly used in cancer treatment. Although they may improve survival, they are also associated with various—and unique—adverse effects, which can be long lasting. Little is known about the experiences of people treated with these therapies. Moreover, their supportive care needs have not been fully explored. Consequently, it is unclear whether existing instruments adequately capture the unmet needs of these patients. The TARGET study seeks to address these evidence gaps by exploring the needs of people treated with these therapies with the aim of developing an unmet needs assessment instrument for patients on biological and precision therapies. Methods and analysis The TARGET study will adopt a multi-methods design involving four Workstreams (1) a systematic review to identify, describe and assess existing unmet needs instruments in advanced cancer; (2) qualitative interviews with patients on biological and precision therapies, and their healthcare professionals, to explore experiences and care needs; (3) development and piloting of a new (or adapted) unmet needs questionnaire (based on the findings of Workstream 1 and Workstream 2) designed to capture the supportive care needs of these patients; and finally, (4) a large-scale patient survey using the new (or modified) questionnaire to determine (a) the psychometric properties of the questionnaire, and (b) the prevalence of unmet needs in these patients. Based on the broad activity of biological and precision therapies, the following cancers will be included: breast, lung, ovarian, colorectal, renal and malignant melanoma. Ethics and dissemination This study was approved by National Health Service (NHS) Heath Research Authority Northeast Tyne and Wear South Research Ethics Committee (REC ref: 21/NE/0028). Dissemination of the research findings will take several formats to reach different audiences, including patients, healthcare professionals and researchers.